Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug 'does not decrease delirium duration'

  • Comment

The cholinesterase inhibiting drug rivastigmine (Exelon) does not decrease the duration of delirium in critically ill patients and could increase mortality, warn Dutch researchers.

They randomised 104 patients diagnosed with delirium to receive an increasing twice daily dose of rivastigmine or placebo, as an adjunct to usual care based on haloperidol. 

The trial was halted early because mortality in the rivastigmine group was higher than in the placebo group - 12 patients died compared with 4 controls.

Median duration of delirium was 5 days in the rivastigmine group, compared with 3 days in the placebo group.

The authors said: “We do not recommend treatment of delirium with rivastigmine for patients in intensive care.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs